{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T10:41:10Z","timestamp":1773225670150,"version":"3.50.1"},"reference-count":50,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T00:00:00Z","timestamp":1644710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Tropical Med Int Health"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Lymphatic filariasis is a serious public health issue. Recent studies showed that a single dosage of triple therapy (Ivermectin, Diethylcarbamazepine, and Albendazole) is more effective than dual therapy (Ivermectin plus Albendazole or Diethylcarbamazepine plus Albendazole) for clearing microfilaria from the blood. We aimed to evaluate the efficacy and safety of triple therapy versus dual therapy in patients infected with microfilaria and communities endemic to lymphatic filariasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>For this systematic review and meta\u2010analysis, we searched MEDLINE, EMBASE, SCOPUS, Cochrane Central Register of Controlled Trials, and Web of Science until 24th June 2021. We included randomized control trials that compared triple with dual therapy given to patients with lymphatic filariasis or endemic communities. This study was registered with PROSPERO (CRD42021266724).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included eight articles after the screening process. Triple therapy caused more clearance of microfilaria in the blood (RR: 1.52; 95% CI: 1.15, 2.02; <jats:italic>p<\/jats:italic>\u00a0=\u00a00.003), while dual therapy caused more clearance of the circulating filariae antigen in the blood (RR: 0.76; 95% CI: 0.65, 0.88; <jats:italic>p<\/jats:italic>\u00a0=\u00a00.0003), both 12\u00a0months after drug administration. The triple therapy had a similar adverse effect compared with the dual therapy group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Based on the greater efficacy in the clearance of microfilaria and the safety of triple therapy, it constitutes a better strategy for the eradication programs of lymphatic filariasis in endemic regions. However, further studies are needed to confirm our results.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tmi.13727","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T11:49:03Z","timestamp":1643197743000},"page":"226-235","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of triple therapy versus dual therapy for lymphatic filariasis: A systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2514-0689","authenticated-orcid":false,"given":"Mohamed T.","family":"Abuelazm","sequence":"first","affiliation":[{"name":"Faculty of Medicine Tanta University  Tanta Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2919-6196","authenticated-orcid":false,"given":"Basel","family":"Abdelazeem","sequence":"additional","affiliation":[{"name":"McLaren Health Care  Flint Michigan USA"},{"name":"Michigan State University  East Lansing Michigan USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7398-0511","authenticated-orcid":false,"given":"Helmy","family":"Badr","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Tanta University  Tanta Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5302-5349","authenticated-orcid":false,"given":"Mohamed","family":"Gamal","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Tanta University  Tanta Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5619-9803","authenticated-orcid":false,"given":"Mohamed","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Tanta University  Tanta Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherief","family":"Abd\u2010elsalam","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Tanta University  Tanta Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,2,13]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"47","article-title":"Neglected tropical diseases: diagnosis, clinical management, treatment and control","volume":"142","author":"Utzinger J","year":"2012","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_7_3_1","unstructured":"Global programme to eliminate lymphatic filariasis: progress report 2017 [Internet]. [cited 2021 Aug 30]. Available from:https:\/\/www.who.int\/publications\/i\/item\/who\u2010wer9344\u2010589\u2010602"},{"key":"e_1_2_7_4_1","unstructured":"WHO.Global programme to eliminate lymphatic filariasis: progress report 2019 [Internet]. [cited 2021 Aug 2]. Available from:https:\/\/www.who.int\/publications\/i\/item\/who\u2010wer9543"},{"issue":"6","key":"e_1_2_7_5_1","first-page":"491","article-title":"Strategies and tools for the control\/elimination of lymphatic filariasis","volume":"75","author":"Ottesen EA","year":"1997","journal-title":"Bull World Health Organ"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(84)90161-5"},{"key":"e_1_2_7_7_1","unstructured":"WHO. Global programme to eliminate lymphatic filariasis: progress report 2018 [Internet]. [cited 2021 Aug 2]. Available from:https:\/\/www.WHO.int\/publications\/i\/item\/who\u2010wer9441\u2010457\u2010472"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495\u2010199753050\u201000004"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000317"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021309"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2005.73.108"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(01)90257-3"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70192-4"},{"issue":"43","key":"e_1_2_7_14_1","first-page":"509","article-title":"Weekly Epidemiological Record, 23 October 2020","volume":"95","author":"World Health Organization","year":"2020","journal-title":"Wkly Epidemiol Rec"},{"key":"e_1_2_7_15_1","unstructured":"World Health Organization. Progress report 2000\u20102009 and strategic plan 2010\u20102020 of the global programme to eliminate lymphatic filariasis: halfway towards eliminating lymphatic filariasis. Geneva PP \u2010 Geneva: World Health Organization;"},{"issue":"41","key":"e_1_2_7_16_1","first-page":"457","article-title":"World Health Organization. Global programme to eliminate lymphatic filariasis: progress report, 2018","volume":"94","author":"World Health Organization","year":"2019","journal-title":"Wkly Epidemiol Rec"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ882"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002839"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706854"},{"key":"e_1_2_7_20_1","unstructured":"World Health Organization (WHO). Guideline: Alternative Mass Drug Administration Regimens to Eliminate Lymphatic Filariasis. Guideline: Alternative Mass Drug Administration Regimens to Eliminate Lymphatic Filariasis. 2017."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30467-4"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006454"},{"key":"e_1_2_7_23_1","first-page":"372","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"29","author":"Page MJ","year":"2021","journal-title":"BMJ"},{"key":"e_1_2_7_24_1","unstructured":"Innovation VH.Covidence systematic review software [Internet]. Melbourne Australia; Available from:http:\/\/www.covidence.org\/"},{"key":"e_1_2_7_25_1","doi-asserted-by":"crossref","unstructured":"HigginsJPT AltmanDG G\u00f8tzschePC J\u00fcniP MoherD OxmanAD et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2011 Oct 18 [cited 2021 Jul 22];343(7829). Available from:https:\/\/www.bmj.com\/content\/343\/bmj.d5928","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39490.551019.BE"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_2_7_30_1","unstructured":"RevMan | Cochrane Training [Internet]. [cited 2021 Aug 3]. Available from:https:\/\/training.cochrane.org\/online\u2010learning\/core\u2010software\u2010cochrane\u2010reviews\/revman"},{"key":"e_1_2_7_31_1","unstructured":"HardyM SamuelaJ KamaM TuicakauM RomaniL WhitfeldMJ . et al.2020;14(3):e0008106."},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008298"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009069"},{"key":"e_1_2_7_34_1","first-page":"30","article-title":"Individual Efficacy and Community Impact of Ivermectin, Diethylcarbamazine, and Albendazole Mass Drug Administration for Lymphatic Filariasis Control in Fiji: A Cluster Randomized Trial","volume":"17","author":"Hardy M","year":"2021","journal-title":"Clin Infect Dis"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009294"},{"key":"e_1_2_7_36_1","first-page":"89","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"4","author":"Sterne JAC","year":"2019","journal-title":"BMJ"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/inthealth\/ihaa087"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002839"},{"issue":"11","key":"e_1_2_7_39_1","first-page":"623","article-title":"The London Declaration on Neglected Tropical Diseases: 5 years on","volume":"110","author":"Molyneux DH","year":"2016","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"e_1_2_7_40_1","unstructured":"Transforming our world: the 2030 Agenda for Sustainable Development | Department of Economic and Social Affairs [Internet]. [cited 2021 Aug 2]. Available from:https:\/\/sdgs.un.org\/2030agenda"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005321"},{"issue":"11","key":"e_1_2_7_42_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008854","article-title":"A community survey of coverage and adverse events following country\u2010wide triple\u2010drug mass drug administration for lymphatic filariasis elimination, Samoa 2018","volume":"14","author":"Ga W","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13238\u2010018\u20100547\u20102"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1050"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/inthealth\/ihaa046"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2005.08.015"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2004.71.471"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2005.08.014"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006454"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1914262"},{"issue":"1","key":"e_1_2_7_51_1","first-page":"58","article-title":"Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis","volume":"2019","author":"Macfarlane CL","year":"2019","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Tropical Medicine &amp; International Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tmi.13727","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tmi.13727","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tmi.13727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T16:32:44Z","timestamp":1693153964000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tmi.13727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,13]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1111\/tmi.13727"],"URL":"https:\/\/doi.org\/10.1111\/tmi.13727","archive":["Portico"],"relation":{},"ISSN":["1360-2276","1365-3156"],"issn-type":[{"value":"1360-2276","type":"print"},{"value":"1365-3156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,13]]},"assertion":[{"value":"2022-02-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}